Company intelligence / Profile preview

Global Stem Cell Technology

Ghent, Belgium

Ownership: Private
Development stage: Other

Overview

Developed and commercialized Arti-Cell Forte, the world's first approved veterinary stem cell product for joint inflammation in horses. Pipeline includes products for horses, dogs, and cats.

Therapeutic areas: RheumatologyOtherMetabolic Disorders
Modalities: Stem cell therapy
Industry: Veterinary

Partnerships

Boehringer Ingelheim (distribution and acquisition)Anacura Group (prior owner and ongoing R&D/production)

Beyond the preview

Go deeper on Global Stem Cell Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Global Stem Cell Technology.

Explore the full profile